Efficacy and safety of rizatriptan versus standard care during long- term treatment for migraine

Headache

Volumn 38, Issue 10, 1998, Pages 764-771

  Block, Gilbert A ^a   Goldstein, Jerome ^b   Polis, Adam ^a   Reines, Scott A ^a   Smith, Mary E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b S Francisco (Calif) Headache Clin   (United States)

Author keywords

5 HT(1D) receptor agonist; Migraine; MK 462; Rizatriptan

Indexed keywords

PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; VERTIGO; VOMITING;

EID: 0032421660     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3810764.x     Document Type: Article

References (13)

1. 1D agonist. Br J Clin Pharmacol. 1997;43:49-54.
2. 1D/1B agonist for migraine. Headache. 1997;37:310. Abstract.
3. Longmore J, Razzaque Z, Hargreaves RJ, et al. Rizatriptan selectively contrasts human middle meningeal over coronary artery: comparison with sumatriptan, Cephalalgia. 1997;17:388-389. Abstract.
4. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol. 1996;53:1132-1137.
5. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of headache. Cephalalgia. 1997;17:647-651.
6. Teall JH, Block GA, Smith E, Jiang K, Reines SA on behalf of the Rizatriptan Recurrence Study Group. Double-blind study of rizatriptan (MK-0462) in acute migraine and migraine recurrence. Headache. 1997;37:334. Abstract.
7. Kramer MS, Matzura-Wolfe D, Getson A, Polis A, Reines SA on behalf of the Rizatriptan Multiple Attack Study Group. Placebo-controlled, double-blind study of rizatriptan in multiple attacks of acute migraine. Headache. 1997;37:318. Abstract.
8. Lines C, Visser WH, Vandormael K, Reines SA on behalf of the Rizatriptan/Sumatriptan Comparison Study Group. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache. 1997;37:319-320. Abstract.
9. Visser WH, Teall JH, Malbecq W, Block GA, Reines SA on behalf of the Rizatriptan Sumatriptan Comparison Study Group. Early onset of action of rizatriptan versus sumatriptan in the acute treatment of migraine. Headache. 1997;37:334-335. Abstract.
10. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35:387-396.
11. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
12. McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman and Hall; 1991.
13. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.